Dengue Vaccine Market Benefits with High CAGR by 2030: Sanofi, Panacea Biotec Ltd., Biological E, GlaxoSmithKline Plc
An immunization to forestall dengue (Dengvaxia®) is authorized and accessible in certain nations for individuals ages 9-45 years of age. The World Health Organization suggests that the immunization just be given to people with affirmed earlier dengue infection disease.
View full press release